Alx Oncology Receives Ind Clearance From U.S. FDA For Alx2004
April 7 (Reuters) - ALX Oncology Holdings Inc ALXO.O:
ALX ONCOLOGY RECEIVES IND CLEARANCE FROM U.S. FDA FOR ALX2004, A NOVEL EGFR-TARGETED ANTIBODY-DRUG CONJUGATE
ALX ONCOLOGY HOLDINGS INC - TO START PHASE 1 TRIAL FOR ALX2004 IN MID-2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Meme Stocks Reappear. Avis Shares Reach New Highs Amid Short Squeeze. Can Retail Investors Still Buy?

SpaceX IPO: Musk Weighs $60 Billion Cursor Deal, and Can It Save xAI?

Intel Q1 2026 Earnings Preview: The Rally is Ahead of the Fundamentals

SK Hynix Q1 2026 Earnings Preview: Memory Chip Prices Surge, Profit Set to Double

Intel Foundry Gains ‘High-Profile’ Customer, Tesla Becomes First Major Customer for 14A Technology

Tradingkey






